Nomura Asset Management CO LTD Biotechnology

Nomura Asset Management CO LTD

$31.8 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
REGN Regeneron Pharmaceuticals, Inc.	$73.7B	$90.4 Million 0.28% of portfolio	86,004	Q1 2023 Reduced 14.44%
VRTX Vertex Pharmaceuticals Inc	$113B	$72 Million 0.23% of portfolio	154,894	Q1 2023 Reduced 37.71%
BMRN Biomarin Pharmaceutical Inc	$11.8B	$34.1 Million 0.11% of portfolio	485,609	Q1 2023 Added 129.87%
ALNY Alnylam Pharmaceuticals, Inc.	$33.7B	$23.5 Million 0.07% of portfolio	85,445	Q1 2023 Added 17.04%
UTHR United Therapeutics Corp	$17B	$9.19 Million 0.03% of portfolio	25,637	Q1 2023 Added 258.01%
MRNA Moderna, Inc.	$15.9B	$7.64 Million 0.02% of portfolio	114,335	Q1 2023 Reduced 0.66%
INCY Incyte Corp	$16.4B	$5.09 Million 0.02% of portfolio	76,955	Q1 2023 Reduced 0.63%
ARGX Argenx Se	$36.2B	$3.75 Million 0.01% of portfolio	6,907	Q1 2022 Reduced 0.85%
TECH Bio Techne Corp	$2.82B	$3.64 Million 0.01% of portfolio	45,550	Q1 2023 Reduced 0.36%
RPRX Royalty Pharma PLC	$14B	$2.88 Million 0.01% of portfolio	101,642	Q1 2023 Added 7.52%
ASND Ascendis Pharma A/S	$7.12B	$2.69 Million 0.01% of portfolio	18,000	Q1 2023 Added 5.11%
NVO Novo Nordisk A S	$190B	$2.45 Million 0.01% of portfolio	20,538	Q4 2022 Reduced 35.96%
ARVN Arvinas, Inc.	$934M	$2.24 Million 0.01% of portfolio	90,870	Q1 2023 New
BPMC Blueprint Medicines Corp	$6.83B	$2.09 Million 0.01% of portfolio	22,557	Q2 2022 Reduced 29.22%
DNLI Denali Therapeutics Inc.	$3.14B	$1.89 Million 0.01% of portfolio	65,033	Q1 2023 New
COGT Cogent Biosciences, Inc.	$587M	$488,000 0.0% of portfolio	45,206	Q3 2024 New
RXRX Recursion Pharmaceuticals, Inc.	$1.29B	$371,000 0.0% of portfolio	56,310	Q1 2022 Sold Out
LEGN Legend Biotech Corp	$6.04B	$360,000 0.0% of portfolio	7,400	Q1 2023 Added 26.67%
RVMD Revolution Medicines, Inc.	$3.59B	$93,000 0.0% of portfolio	2,064	Q2 2021 New
RARE Ultragenyx Pharmaceutical Inc.	$2.97B	$92,000 0.0% of portfolio	1,669	Q1 2021 Sold Out
PCVX Vaxcyte, Inc.	$5.26B	$92,000 0.0% of portfolio	806	Q1 2023 New
JAZZ Jazz Pharmaceuticals PLC	$7.79B	$64,000 0.0% of portfolio	583	Q3 2022 Added 0.04%
EXEL Exelixis, Inc.	$10.6B	$39,000 0.0% of portfolio	1,520	Q1 2022 Reduced 44.74%
ETNB 89bio, Inc.	$417M	$0 0.0% of portfolio	0	Q1 2023 New
ADMA Adma Biologics, Inc.	$3.22B	$0 0.0% of portfolio	0	Q3 2024 New
APLS Apellis Pharmaceuticals, Inc.	$3.24B	$0 0.0% of portfolio	0	Q1 2023 New
RNA Avidity Biosciences, Inc.	$1.66B	$0 0.0% of portfolio	0	Q3 2024 New
BNTX Bio N Tech Se	$29.4B	$0 0.0% of portfolio	0	Q1 2023 New
BBIO Bridge Bio Pharma, Inc.	$5.41B	$0 0.0% of portfolio	0	Q1 2021 New
CLDX Celldex Therapeutics, Inc.	$1.19B	$0 0.0% of portfolio	0	Q1 2023 New
CRNX Crinetics Pharmaceuticals, Inc.	$2.12B	$0 0.0% of portfolio	0	Q3 2024 New
CYTK Cytokinetics Inc	$4.58B	$0 0.0% of portfolio	0	Q1 2023 New
DAWN Day One Biopharmaceuticals, Inc.	$956M	$0 0.0% of portfolio	0	Q3 2024 New
GMAB Genmab A/S	$13.1B	$0 0.0% of portfolio	0	Q1 2023 New
IDYA Ideaya Biosciences, Inc.	$1.15B	$0 0.0% of portfolio	0	Q3 2024 New
IMVT Immunovant, Inc.	$3.55B	$0 0.0% of portfolio	0	Q4 2020 New
INSM Insmed Inc	$10.6B	$0 0.0% of portfolio	0	Q1 2023 New
NTLA Intellia Therapeutics, Inc.	$769M	$0 0.0% of portfolio	0	Q1 2023 New
IONS Ionis Pharmaceuticals Inc	$4.67B	$0 0.0% of portfolio	0	Q3 2021 Sold Out
IOVA Iovance Biotherapeutics, Inc.	$958M	$0 0.0% of portfolio	0	Q1 2023 New
KRYS Krystal Biotech, Inc.	$4.01B	$0 0.0% of portfolio	0	Q1 2023 New
LBPH Longboard Pharmaceuticals, Inc.	$815M	$0 0.0% of portfolio	0	Q3 2024 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.58B	$0 0.0% of portfolio	0	Q1 2023 New
MRUS Merus N.V.	$1.91B	$0 0.0% of portfolio	0	Q3 2024 New
MIRM Mirum Pharmaceuticals, Inc.	$1.79B	$0 0.0% of portfolio	0	Q1 2023 New
MLTX Moon Lake Immunotherapeutics	$1.65B	$0 0.0% of portfolio	0	Q3 2024 New
NRIX Nurix Therapeutics, Inc.	$926M	$0 0.0% of portfolio	0	Q1 2023 New
NUVL Nuvalent, Inc.	$3.68B	$0 0.0% of portfolio	0	Q3 2024 New
OLMA Olema Pharmaceuticals, Inc.	$243M	$0 0.0% of portfolio	0	Q3 2024 New
PLRX Pliant Therapeutics, Inc.	$531M	$0 0.0% of portfolio	0	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.